18+ · Research Use Only · Not for Human Consumption
Retatrutide · Phase 3 · Ongoing
TRIUMPH-5
TRIUMPH-5 is a phase 3 trial of retatrutide against tirzepatide in adults who have obesity, registered as NCT06662383 and not yet reported (ClinicalTrials.gov, checked 23 September 2026).
Primara Labs sells some of the compounds covered here. Every figure on this page links to its source and the date it was checked.
Design
Trial design and sources
- Compound
- Retatrutide
- Phase
- 3
- Population
- Adults who have obesity
- Participants randomised
- Not published
- Duration
- Not published
- Primary endpoint
- Compared with tirzepatide
- Estimand
- Not stated in the source read
- Read out
- Not yet reported
- ClinicalTrials.gov record, active, not recruiting open · checked 23 September 2026
- Registry: NCT06662383
Questions
TRIUMPH-5, answered
What did TRIUMPH-5 find?
TRIUMPH-5 is a phase 3 trial of retatrutide against tirzepatide in adults who have obesity, registered as NCT06662383 and not yet reported (ClinicalTrials.gov, checked 23 September 2026).
When will TRIUMPH-5 report?
TRIUMPH-5 is active and not recruiting on ClinicalTrials.gov (NCT06662383); no results have been published. Checked 23 September 2026.